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Expression of Basal-Cell Adhesion Molecule (B-CAM) in
Human Epidermis
To the Editor:
I read with interest the recent article by SchoÈn et al on the
expression of basal-cell adhesion molecule (B-CAM) in human skin
(SchoÈn et al, 2000) documenting association of B-CAM expression
with activated states of keratinocytes. The authors provide
convincing evidence that, besides its known function as a laminin
receptor, B-CAM may be involved in cell±cell interaction or
migration.
In this context I would like to bring to your attention data
regarding B-CAM expression in human skin that might not have
been accessible to the authors at the time their manuscript was
submitted. We have been analyzing B-CAM expression in normal
and diseased human skin utilizing the monoclonal antibody G253
that has also been employed in the paper by SchoÈn et al. Contrary
to their observation, but in line with previous ®ndings (Garin-
Chesa et al, 1994), the majority of specimen from normal human
epidermis exhibited B-CAM positive suprabasal keratinocytes. In
contrast, B-CAM expression in fetal epidermis was restricted to
basal keratinocytes. The outer root sheath of hair follicles in both
fetal as well as adult human skin regularly exhibited a B-CAM
positive phenotype. The level of B-CAM expression was higher in
psoriasis and contact dermatitis. We interpret our observations as
evidence for B-CAM being a keratinocyte differentiation marker
(Bernemann et al, 2000). This notion is supported by the effects of
Ca2+ levels on the B-CAM phenotype of keratinocytes as described
by SchoÈn et al.
Wolf-Henning Boehncke
Department of Dermatology, Frankfurt University
Medical School, Frankfurt, Germany
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Maternal Transmission of the 3 bp Deletion within Exon 7 of
the STS Gene in Steroid Sulfatase De®ciency
To the Editor:
Steroid sulfatase (STS) enzyme (EC 3.1.6.2) is present in the
microsomal fraction of the cell and is capable of hydrolyzing
sulfated sterols (Hobkirk, 1985; Dibbelt and Kuss, 1991). STS
de®ciency is the biochemical defect in X-linked ichthyosis (XLI), a
disease that clinically presents dark, adhesive, and regular scales of
skin (Shapiro and Weiss, 1978). STS assay or FISH analyzes allow
an XLI diagnosis and identify XLI-carriers (Baden et al, 1980;
Epstein and Leventhal, 1981; Okano et al, 1985; Hermann et al,
1987; Matsumoto et al, 1990; Aviram-Goldring et al, 2000). STS
enzyme is encoded by the STS gene on the short arm of the
X-chromosome (Muller et al, 1981). Most STS enzyme de®cient
patients present large deletions of the entire STS gene and ¯anking
sequences (Bonifas et al, 1987; Shapiro et al, 1989; Cuevas-
Covarrubias et al, 1997; Aviram-Goldring et al, 2000). Only a few
point mutations or partial deletions have been identi®ed (Bonifas
et al, 1987; Ballabio et al, 1989; Shapiro et al, 1989; Basler et al,
1992; Nomura et al, 1995; Alperin and Shapiro, 1997; Morita et al,
1997; Aviram-Goldring et al, 2000; Oyama et al, 2000; Sugawara et
al, 2000; Valdes et al, 2000). In this study, we describe an XLI
patient with the ®rst 3 bp intragenic deletion of the STS gene
causing XLI and demonstrate the maternal transmission of this
molecular defect.
MATERIALS AND METHODS
Patient The patient was referred as having ichthyosis to the General
Hospital of Mexico. He was the only child of the family. The patient
and his mother were informed about the characteristics of the study and
they agreed to participate. Protocol was evaluated and approved by the
Ethics Committee. The patient showed a moderate degree of
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involvement on the trunk, back, and upper extremities and more severe
involvement on the lower extremities. No clinical ®ndings were
observed in his mother.
STS assay STS activity was determined in leukocytes of the XLI
patient and his mother using 7-[3H]-dehydroepiandrosterone sulfate as
described elsewhere (Miranda-Duarte et al, 1999).
Mutation detection DNA extraction was performed in the
conventional way (Lench et al, 1988). All exons of the STS gene were
analyzed by polymerase chain reaction (PCR). The conditions and
primers to amplify these regions are described elsewhere (Ballabio et al,
1990a; Oyama et al, 2000; Valdes-Flores et al, 2000). DNA sequence
analysis was performed in an ABI Prism Genetic Analyzer (Perkin Elmer,
CA, USA).
RESULTS AND DISCUSSION
The XLI patient had no STS activity (0.00 pmol per mg protein
per h), corroborating the XLI diagnosis. STS activity of his mother
was very low (0.30 pmol per mg protein per h versus 0.85 pmol per
mg protein per h of normal control). PCR analysis of the XLI
patient showed normal ampli®cation of all exons of the STS gene.
In the DNA sequence analysis, the loss of nucleotides AAG at
positions 1252±1254 within exon 7 of the STS gene was observed
(Fig 1). DNA analysis of the patient's mother showed an
heterozygote state for this condition (Fig 1).
Most XLI patients lack the entire STS gene and ¯anking
sequences. These large deletions appear to be due to unequal
recombination between low copy number repeats on either side of
the STS gene (Ballabio et al, 1990b; Yen et al, 1990). In this study,
we observed AAGdel1252 of the STS gene corresponding to the
last two nucleotides of the codon 327 and the ®rst one of the codon
328 (Fig 2). This indicates that homologous recombination does
not apply to all STS gene deletions. As STS activity of the patient's
mother was very low, we analyzed her DNA and found an
heterozygote state for the same molecular defect. It has also been
reported that most sporadic cases in XLI correspond to inherited
cases (Cuevas-Covarrubias et al, 1998), and we con®rmed it in our
family. Although the nucleotides involved in AAGdel1252 did not
correspond to a speci®c codon, this 3 bp deletion only resulted in
the absence of glutamine at position 327 of the STS enzyme
(DE327) and not in a frameshift mutation. This amino acid is found
in the C-terminal region after the second N-linked glycosylation
site. It has been suggested that the N-terminal domain contains the
catalytic site whereas the C-terminal region probably contains the
substrate binding site (Stein et al, 1989). So, the mutation reported
here would be affecting the substrate binding region of the STS
enzyme. Additional studies will be required to elucidate if this
mutation affects half-life, folding, dimerization, or post-translational
processing of STS enzyme.
The majority of patients have large deletions of the STS gene
and ¯anking sequences; however, partial deletions and point
mutations in exon and intron regions have also been reported.
Now, we report the ®rst intragenic deletion of 3 bp of the STS
gene observed in XLI. These data indicate that all molecular
defects occur in XLI.
This study was supported by CONACYT, MeÂxico, project number 31020-M and
grant 96072.
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Figure 1. DNA sequence of the STS gene of
the XLI patient and his mother. DNA
sequence of exon 7 of the STS gene of the XLI
patient (middle line), carrier mother (lower line),
and normal control (upper line), only a small
fragment is shown (starting at nucleotide 1241).
The missing region of 3 bp observed in the XLI
patient is underlining in the normal control. The
heterozygote state of the mother is observed
starting at nucleotide 1252. W = A + T, R =
G + A, K = T + G, Y = C + T, M = A + C.
Figure 2. Amino acid sequence of the STS polypeptide. Normal
sequence of exon 7 of the STS gene with the respective amino acids
(upper line) and the effect observed in the XLI patient described in the
text (lower line). A 3 bp deletion (shadowed area) only results in the loss
of glutamine (only nucleotides 1242±1280 and amino acids 324±335 are
shown). The arrow indicates the nucleotides conforming the new codon
that corresponds to the contiguos codon in the normal amino acid
sequence. H, his; V, val; E, glu; S, ser; K, lys; G, gly; I, ile.
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Animal Model of Sclerotic Skin. IV: Induction of Dermal
Sclerosis by Bleomycin is T Cell Independent
To the Editor:
Systemic sclerosis (SSc) is a chronic connective tissue disorder
characterized by excessive collagen production by activated
®broblasts resulting in the deposition in the dermis (Krieg and
Meurer, 1988). Although a number of attempts have been
made, the pathogenesis of SSc still remains unknown. Previous
studies have suggested immunologically mediated mechanisms
involving immunocytes in®ltrating in the dermis. In its early
stage, SSc is associated with intense mononuclear cell in®ltration
(Fleishmajer et al, 1977; Roumm et al, 1984), which is mainly
composed of T lymphocytes, mast cells, and monocyte/
macrophages, along with a smaller number of B cells and
plasma cells. Several in¯ammatory or ®brogenic cytokines
released from T cells and monocyte/macrophages are suggested
to play an important role in the induction of tissue ®brosis in
the affected sites. Bleomycin (BLM) is an antitumor antibiotic
used for the therapy of a variety of cancers. It is well known
that pulmonary ®brosis can be induced in patients treated with
BLM as a side-effect. Thus, BLM-induced lung ®brosis is an
established animal model, resembling human pulmonary ®brosis
histologically and biochemically (Adamson and Bowden, 1974;
Aso et al, 1976; Chandler, 1990). In vivo T cell depletion with
anti-T cell antibodies has been shown to either reduce or
completely abrogate BLM-induced pulmonary ®brosis (Thrall et
al, 1980; Piguet et al, 1989). On the other hand, results of
athymic nude mice lacking functional T lymphocytes have been
controversial. One study showed histologically similar ®brosis in
nude, euthymic mice after BLM treatment (Szapiel et al, 1979),
whereas another study showed that BLM was not ®brogenic in
nude mice (Schrier et al, 1983). On the contrary, a recent study
has demonstrated that BLM-induced lung ®brosis occurred in
C57BL/6 SCID and (C57BL/63CB.17)F1SCID mice compar-
able with that seen in wild-type mice, suggesting that the initial
induction of lung ®brosis is lymphocyte-independent (Lake-
Bullock et al, 1999). We have recently established a mice model
for scleroderma by repeated local injections of BLM (Yamamoto
et al, 1999a). In this study, in order to determine the role of
lymphocytes in the induction of dermal sclerotic lesions, we
examined whether dermal sclerosis can be induced in SCID
mice using our method. Speci®c pathogen-free, 6-wk-old,
female BALB/C mice (wild-type) and age- and sex-matched
BALB/C SCID mice (weighing about 20 g) were purchased
from Clea (Tokyo, Japan), and maintained with food and water
ad libitum. BLM was dissolved in phosphate-buffered saline
(PBS) at a concentration of 100 mg per ml, and sterilized by
®ltration (0.2 mm). One hundred microliters of BLM or PBS
were injected subcutaneously into the shaved back of mice
every other day for 4 wk with a 27-gauge needle. The back
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